Market cap
$279 Mln
Revenue (TTM)
$121 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 10.12 | 15.56 | 31.36 | -9.38 | -2.48 |
| EBIT | 170.11 | 185.22 | 72.85 | 23.67 | 12.93 |
| Net Profit | 165.45 | 183.35 | 93.76 | 22.30 | 14.39 |
| EPS | 165.94 | 189.15 | 93.49 | 22.15 | 11.23 |
| Book Value | -- | -- | -6.50 | -20.56 | -12.51 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -2.65 | -6.57 | -2.41 | -8.25 | -2.31 |
| Net Margin
| -- | -- | -3.14 | -- | -- |
| Return on equity
| -23.77 | -15.01 | -2.70 | -7.32 | -30.79 |
| Return on Capital
| -20.93 | -13.24 | -- | -6.22 | -26.85 |
| Return on Assets
| -18.68 | -11.83 | -1.85 | -5.54 | -23.82 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.18 | 0.17 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
-6.22
|
-26.85
|
-29.71
|
-4.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-2.70
Lower than Peers by 21.67
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
-2.70
|
-7.32
|
-30.79
|
-33.21
|
-5.19
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-1.85
Lower than Peers by 4.71
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
-1.85
|
-5.54
|
-23.82
|
-26.68
|
-4.27
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
-2.41
Lower than Peers by 18.23
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
-2.41
|
-8.25
|
-2.31
|
2.61
|
-12.42
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
-3.14
Lower than Peers by 11.37
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
-3.14
|
-9.64
|
-47.02
|
-68.44
|
-9.51
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
31.36
Higher than Peers by 23.31
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
31.36
|
-0.06
|
-0.01
|
-0.23
|
0.06
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
72.85
Higher than Peers by 64.59
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
72.85
|
-236.72
|
-187.58
|
116.27
|
-4.98
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
93.76
Higher than Peers by 86.03
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
93.76
|
80.70
|
31.79
|
-456.34
|
-459.43
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
93.49
Higher than Peers by 83.09
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
93.49
|
0.81
|
0.32
|
-4.56
|
-4.54
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
-0.57
Lower than Peers by 5.45
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
-0.57
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
0.18
|
0.17
|
0.13
|
0.11
|
|
Peer Median
|
0.60
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
0.01
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.48
Higher than Peers by 2.83
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
4.48
|
4.72
|
4.88
|
5.26
|
6.07
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
3.19
Higher than Peers by 1.99
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
3.19
|
3.86
|
3.85
|
4.47
|
4.65
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
-0.46
Lower than Peers by 5.23
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
-0.46
|
-5.34
|
-1.18
|
1.37
|
-29.66
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
24.09
Higher than Peers by 2.81
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
24.09
|
21.00
|
19.68
|
21.82
|
22.16
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.59
Higher than Peers by 0.19
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
0.59
|
0.57
|
0.51
|
0.39
|
0.45
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
76.54
|
76.08
|
92.21
|
75.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
158.72
|
200.63
|
306.41
|
220.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
43.44
|
49.12
|
72.88
|
48.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
191.82
|
227.58
|
325.74
|
247.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
-12.96
|
-4.30
|
-4.01
|
-29.16
|
|
Peer Median
|
37.91
|
--
|
--
|
--
|
--
|
Price / Book Value
2.05
Lower than Peers by 5.64
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
2.05
|
0.98
|
1.57
|
1.56
|
1.52
|
|
Peer Median
|
7.69
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.56
|
--
|
--
|
--
|
--
|
EV/EBITDA
523.47
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
523.47
|
-30.67
|
39.69
|
16.74
|
-69.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
278
Lower than Peers by 2,291
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
278
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,569
|
--
|
--
|
--
|
--
|